MONTREAL, QUEBEC--(Marketwire - Dec. 2, 2010) - A5 Laboratories Inc. (A5 Labs) (OTCBB:AFLB) announced today that its European partner has begun the preparation and production of the VI-1718 interferon product. Using A5 Labs production technology, it is anticipated that approximately 2,000 doses of the VI-1718 will be manufactured with certificates of analysis in the next 4 weeks. A5 Labs expects that it will begin a multi-center production and in-vitro test of the interferon product to establish proof of concept potency in the next 6 to 8 weeks.
"I am extremely pleased to report to our shareholders the start of the production of VI-1718. In the next 6 to 8 weeks we plan further production and testing the product for its potency and efficacy in independent labs, the results of which will be a significant milestone towards initiation of submission for animal and human clinical trials," said Dr. Richard Azani, President and CEO.
More information about the Company is available at its corporate website at www.a5labs.com.
About A5 Labs:
A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.
Safe Harbor Statement:
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5, and specifically the production and testing of A5's interferon product, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.